Scleroderma: A treatable disease
Joseph H. Korn, MD
Director, Arthritis Center, Boston University School of Medicine; Chief, Rheumatology Section, Boston Medical Center
Address: Joseph H. Korn, MD, Chief, Rheumatology Section, Boston University Medical Center, 80 East Concord Street, Boston, MA 02118
The author has indicated that he has received grant or research support from the Actelion, Biogen, and Genzyme corporations and from the National Institutes of Health; serves as a consultant for the Actelion and Genzyme corporations; and is on the speaker’s bureau of the Actelion corporation.
This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.
Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.
ABSTRACTMany effective treatments for scleroderma have emerged in recent years, including bosentan, an endothelin receptor antagonist, and epoprostenol, a prostacyclin, both of which target vasoconstriction. Cyclophosphamide may soon be proven effective against interstitial lung disease.